Association of Serum FAM19A5 with Cognitive Impairment in Vascular Dementia

Li, Juan; Li, Shoulin; Song, Yihong; Zhou, Wei; Zhu, Xiaohao; Xu, Suo; Ma, Yihong; Zhu, Chunlin

doi:10.1155/2020/8895900

“…Research Object. We followed the methods of Dr. Juan Li et al [9]. A total of 146 VAD patients admitted to our hospital from February 2015 to February 2020 were selected as the VAD group, including 70 females and 76 males, aged 40-75 years, with an average of 69:75 ± 7:23 years old.…”

Section: Methodsmentioning

confidence: 99%

The Relationship between Serum Amyloid A Level and Cognitive Dysfunction in Patients with Vascular Dementia: Preliminary Findings

Xu

¹

,

He

²

,

Huang

³

2021

BioMed Research International

View full text Add to dashboard Cite

Objective. This study was aimed at investigating the relationship between serum amyloid A (SAA) levels and cognitive dysfunction in patients with vascular dementia (VAD). Methods. Using cross-sectional research methods, 146 patients with VAD were selected as the VAD group and 70 normal people were selected as the NC group. Upon admission, the clinical and biochemical characteristics of the two groups of study subjects were collected, and the MMSE scale was used to assess cognitive function. A sandwich enzyme-linked immunosorbent assay was used to detect SAA levels. Results. There was no significant difference in clinical data and biochemical characteristics in the VAD group ( p > 0.05 ). Compared with the VAD group, the NC group has a higher level of education ( p < 0.05 ). The SAA level of the VAD group was higher than that of the NC group, and there was a significant difference ( p < 0.05 ). Spearman correlation analysis showed that SAA and MMSE in the VAD group were negatively correlated. Further multiple regression analysis showed that the serum amyloid A level is an independent risk factor for cognitive dysfunction in VAD patients. Conclusion. The level of SAA in VAD patients is significantly increased, which can be used as a potential peripheral blood marker to predict cognitive impairment in VAD patients.

show abstract

“…As people's lifestyle changes and life pressure increases, the prevalence of VaD remains high. The latest epidemiological studies show that the number of people diagnosed with dementia will rapidly increase to 131 million by 2050 [ 5 , 6 ]. Hypertension, diabetes, smoking, hyperlipidemia, and arrhythmia are common causes of VaD [ 7 , 8 ].…”

Section: Introductionmentioning

confidence: 99%

Decreased Serum NCAM Levels Associated with Cognitive Impairment in Vascular Dementia

Zhao

¹

,

Lü

²

,

Li

³

et al. 2021

View full text Add to dashboard Cite

Objective. Neural cell adhesion molecule (NCAM), a glycoprotein widely distributed in the brain, has recently been shown to regulate neuroplasticity. However, the role of NCAM in vascular dementia (VaD) is still unclear. The purpose of this study is to determine whether NCAM is involved in the course of VaD. Methods. Continuous recruitment of VaD patients and control population to join this study. Doctors or nurses are responsible for collecting their clinical characteristics including age, gender, formal education, heart rate, supine systolic blood pressure, supine diastolic blood pressure, fasting glucose, high-density lipoprotein, and low-density lipoprotein. Each participant received the Montreal Cognitive Assessment (MoCA) scale after being enrolled in the group. At the same time, their peripheral blood was collected, and their serum NCAM levels were measured by enzyme-linked immunosorbent assay (ELISA). Results. 98 VaD patients and 83 age- and sex-matched controls were enrolled. There was no significant statistical difference between the VaD group and the control group in terms of the comparison of clinical characteristics ( p > 0.05 ). The MoCA score of VaD patients was significantly lower than that of the controls ( 27.9 ± 1.4 vs. 23.0 ± 2.1 points, p < 0.001 ). In addition, the circulating NCAM level of VaD patients was also significantly lower than that of controls ( 21.7 ± 3.8 vs. 17.6 ± 4.2 ng/mL, p < 0.001 ). The circulating NCAM level of VaD patients was significantly positively correlated with MoCA score ( r = 0.285 , p = 0.026 ). After adjusting for clinical characteristics, circulating NCAM levels are still an independent pathogenic factor of VaD (regression coefficient = 0.223 , p = 0.034 ). Conclusions. VaD patients have low circulating NCAM levels, which can be used as a potential predictor of VaD.

show abstract

“…According to statistics from the World Health Organization (WHO), there are cur-rently about 36 million people with dementia in the world. By 2050, this number will reach to 115 million, and VaD accounts for about 20% of them, second only to Alzheimer's disease (AD) [3]. It is reported that the prevalence of VaD in developed countries ranges from 1% to 4%, while the prevalence of VD in developing countries is about 8%, and the prevalence of VD in the elderly is rising rapidly [4].…”

Section: Introductionmentioning

confidence: 99%

Decreased Levels of Serum IL‐34 Associated with Cognitive Impairment in Vascular Dementia

Wang

¹

,

Lü

²

,

Ning

³

et al. 2021

BioMed Research International

View full text Add to dashboard Cite

Objective. Interleukin- (IL-) 34 is a new type of cytokine with neuroprotective effects discovered in recent years. However, the relationship between IL-34 and vascular dementia (VaD) has not yet been elucidated. The purpose of this study is to determine whether IL-34 is involved in cognitive impairment of VaD. Methods. From January 2017 to December 2020, 84 VaD patients and 60 healthy controls who attended Qingpu Branch of Zhongshan Hospital were prospectively included in the study. Once included in the study, demographic features of all research subjects are collected. They include age, gender, education, white blood cells (WBC), neutrophil, lymphocyte, systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting blood glucose (FBG), triglycerides (TG), and total cholesterol (TC). Meanwhile, the Montreal Cognitive Assessment (MoCA) scale was used to assess the cognitive function of participants. The serum IL-34 level was determined by enzyme-linked immunosorbent assay (ELISA). Results. There was no significant difference between the demographic features of VaD patients and healthy controls ( p > 0.05 ). However, the serum IL-34 levels of VaD patients and healthy controls are 27.6 ± 3.9 pg / ml and 41.8 ± 6.0 pg / ml , respectively, and there is a significant statistical difference between them ( p < 0.001 ). The results of bivariate correlation analysis showed that serum IL-34 levels were significantly positively correlated with MoCA scores ( r = 0.371 , p = 0.023 ). Further regression analysis showed that IL-34 was still correlated with MoCA after adjusting for demographic features ( β = 0.276 , p = 0038 ). Conclusions. Serum IL-34 levels in VaD patients were significantly reduced, which may be an independent predictor of cognitive impairment in VaD patients.

show abstract

Association of Serum FAM19A5 with Cognitive Impairment in Vascular Dementia

Cited by 18 publications

References 32 publications

The Relationship between Serum Amyloid A Level and Cognitive Dysfunction in Patients with Vascular Dementia: Preliminary Findings

The Relationship between Serum Amyloid A Level and Cognitive Dysfunction in Patients with Vascular Dementia: Preliminary Findings

Decreased Serum NCAM Levels Associated with Cognitive Impairment in Vascular Dementia

Decreased Levels of Serum IL‐34 Associated with Cognitive Impairment in Vascular Dementia

Contact Info

Product

Resources

About